ACD’s Biomarker Solution
In the world of personalized medicine, biomarkers play increasingly critical role in drug development. They:
- serve as drug targets
- evaluate efficacy or side effects
- select right patients for clinical trial
- enable earlier go/no go decisions in advancing a compound to the next phase
After the new drug or therapy is on the market, biomarkers form the bedrock of companion diagnostic tests that identify suitable patients for the therapy, predict outcome and monitor the progression.
It can be relatively easy to come up with candidate biomarkers. The hard part is to validate them. Due to the heterogeneity of diseases and patient population, evaluation of biomarker within the context of tissue structure has become increasingly important. The difficulty in developing effective in situ assays has emerged as a significant hurdle for biomarker validation, blocking the path to personalized medicine.
ACD’s RNAscope™ technology is a true toolset which can be used for any disease that involves changes in gene expression. It offers unprecedented flexibility that adapts and evolves with every step and turn of your drug development process. Custom assays for any RNA biomarkers can be developed within 3 weeks. More importantly, ACD guarantees the sensitivity and specificity of these assays, eliminating the risk in development timeline.
ACD provides clinical grade assay development and biomarker analysis services to speed up biomarker validation. ACD also partners with pharmaceutical and biotech companies to support clinical trials and turn validated biomarkers into successful companion diagnostic tests.
RNAscope™ can significantly accelerate biomarker validation
(Mouse over each box for details)